{"title":"Prior employment status and obesity do not predict post-stroke fatigue","authors":"Zachary Cooper, N. Gilles, S. Levine, J. Weedon","doi":"10.2217/fnl-2021-0016","DOIUrl":"https://doi.org/10.2217/fnl-2021-0016","url":null,"abstract":"Aim: To investigate whether prior employment status or obesity pose as risk factors for post stroke fatigue in patients following an ischemic stroke. Materials & methods: A total of 121 patients with a confirmed diagnosis of ischemic stroke in the past 3 years were enrolled into the study. Post-stroke fatigue (PSF) was assessed using the fatigue assessment scale (no PSF ≤21, PSF 22–50). Patients were then identified based on their employment status (previously worked) or obesity (BMI) and compared with the presence of PSF. Results: A Fisher’s exact test was applied to determine the association between PSF and obesity (p = 1.000). A Fisher’s exact test was applied to show the association between PSF and employment status (p = 0.384). In logistic regression, employment status did not independently predict dichotomized fatigue assessment scale (adjusted odds ratio 1.34, 95% CI: 0.51–3.50, p = 0.557). Conclusion: Previous employment status and obesity did not independently predict PSF in an urban, minority community.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46874095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Plain language summary of the effects of iclepertin (BI 425809) on cognition in patients with schizophrenia","authors":"K. Nakagome","doi":"10.2217/fnl-2022-0008","DOIUrl":"https://doi.org/10.2217/fnl-2022-0008","url":null,"abstract":"ClinicalTrials.gov NCT number: NCT02832037","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46197279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Kushida, M. Thorpy, J. Flygare, A. Roy, J. Dubow, D. Seiden
{"title":"Once-nightly sodium oxybate (FT218) improved symptoms in people with narcolepsy: a plain language summary of publication","authors":"C. Kushida, M. Thorpy, J. Flygare, A. Roy, J. Dubow, D. Seiden","doi":"10.2217/fnl-2022-0005","DOIUrl":"https://doi.org/10.2217/fnl-2022-0005","url":null,"abstract":"This is a plain language summary of an article originally published in the journal Sleep. Once-nightly sodium oxybate (ON-SXB for short; also known as FT218) is a potential treatment for excessive daytime sleepiness (EDS for short) and sudden muscle weakness known as cataplexy. The US Food and Drug Administration (FDA) is deciding whether to approve ON-SXB to be prescribed to adults with narcolepsy. The REST-ON clinical study looked at whether ON-SXB was better than a substitute that had no medicine in it (called a placebo) at treating narcolepsy symptoms. The results of this study showed that people who took ON-SXB were able to stay awake longer during the day, felt less sleepy in the daytime, had less cataplexy, and were more improved overall than people who took placebo. Common side effects with ON-SXB were nausea, vomiting, dizziness, bedwetting, and headache. If approved by the FDA, people with narcolepsy may have the option to choose a form of sodium oxybate that they only have to take once at bedtime. They could avoid taking a second middle-of-the-night dose. ClinicalTrials.gov NCT number: NCT02720744","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"1 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43317898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mehdi Borni, Wiem Boudabbous, Souhir Abdelmouleh, M. Boudawara
{"title":"A rare case of Corynebacterium accolens isolated from brain abscess following mild nonpenetrating head trauma","authors":"Mehdi Borni, Wiem Boudabbous, Souhir Abdelmouleh, M. Boudawara","doi":"10.2217/fnl-2021-0012","DOIUrl":"https://doi.org/10.2217/fnl-2021-0012","url":null,"abstract":"Corynebacterium accolens ( C. accolens) was first described by Neubauer et al. in 1991. Infection of the CNS with this germ is still extremely rare and no previous case of brain abscess was reported yet. The authors report here the first case of brain abscess due to C. accolens, in a 60-year-old male patient after a nonpenetrating mild head trauma. Diagnosis was made after abscess aspiration followed by staining and incubation of the aspirate. Postoperative course was uneventful. This is the first reported case of brain abscess associated with C. accolens. The risk factors for this infection remain unclear. However, and for some unknown reasons, Corynebacterium may favor previously traumatized sites.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49414924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Using the EQ-5D to measure caregiver health-related quality of life in rare pediatric disease: a study in aromatic L-amino acid decarboxylase deficiency","authors":"S. Acaster, K. Williams, H. Skrobanski, K. Buesch","doi":"10.2217/fnl-2022-0004","DOIUrl":"https://doi.org/10.2217/fnl-2022-0004","url":null,"abstract":"Aims: To evaluate how well the EQ-5D-5L, a generic preference-based measure of health-related quality of life, captures caregiver burden in a rare pediatric neurotransmitter disease. Materials & methods: Caregivers (n = 14) of individuals with aromatic L-amino acid decarboxylase (AADC) deficiency completed qualitative interviews on their experience as a caregiver, the EQ-5D-5L and a background questionnaire. Qualitative and quantitative data were compared to determine whether there was concordance or discordance in the findings. Results: No caregivers reported problems with mobility and self-care in either the qualitative interviews or on the EQ-5D-5L, and there was general concordance for pain/discomfort and anxiety/depression. However, discordance was found for usual activities, with 79% reporting no problems with this dimension on the EQ-5D-5L, compared with 100% describing substantial limitations during the interviews. Conclusion: The EQ-5D-5L may not be appropriate to evaluate caregiver burden in AADC deficiency, where caregivers' perceptions of “usual activities” differ substantially from the general population.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46566007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Magnetoencephalography: at the forefront of optimizing epilepsy surgery","authors":"Saleem Malik","doi":"10.2217/fnl-2022-0006","DOIUrl":"https://doi.org/10.2217/fnl-2022-0006","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47327170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Symptoms and impacts of nonsense mutation Duchenne muscular dystrophy at different stages of ambulation","authors":"K. Williams, K. Buesch, S. Acaster","doi":"10.2217/fnl-2021-0013","DOIUrl":"https://doi.org/10.2217/fnl-2021-0013","url":null,"abstract":"Aim: To describe the experience of nonsense mutation Duchenne muscular dystrophy (DMD) across different health states in the DMD natural history model. Materials and methods: Qualitative interviews were conducted with UK caregivers (n = 10) of individuals with nonsense mutation DMD treated with ataluren. Results: Interviews were conducted with caregivers of individuals in the early ambulatory (n = 6), late ambulatory (n = 3) and transfers (n = 3) health states. Increasing health state severity was related to decreased physical function, which impacted daily and social activities, emotional well-being and caregiver burden. Conclusion: Declining physical function can impair daily life and impact the health-related quality of life of individuals and their caregivers. Delaying progression between health states has the potential to prevent loss of function and decline in health-related quality of life.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46527452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nairita Ahsan Faruqui, Durdana Hossain Prium, Sadrina Afrin Mowna, M. Ullah, Yusha Araf, Bishajit Sarkar, U. S. Zohora, Mohammad Shahedur Rahman
{"title":"Gut microorganisms and neurological disease perspectives","authors":"Nairita Ahsan Faruqui, Durdana Hossain Prium, Sadrina Afrin Mowna, M. Ullah, Yusha Araf, Bishajit Sarkar, U. S. Zohora, Mohammad Shahedur Rahman","doi":"10.2217/fnl-2020-0026","DOIUrl":"https://doi.org/10.2217/fnl-2020-0026","url":null,"abstract":"The gastrointestinal tract of every healthy human consists of a unique set of gut microbiota that collectively harbors a diverse and complex community of over 100 trillion microorganisms, including bacteria, viruses, archaea, protozoa and fungi. Gut microbes have a symbiotic relationship with our body. The composition of the microbiota is shaped early in life by gut maturation, which is influenced by several factors. Intestinal bacteria are crucial in maintaining immune and metabolic homeostasis and protecting against pathogens. Dysbiosis of gut microbiota is associated not only with intestinal disorders but also with extraintestinal diseases such as metabolic and neurological disorders. In this review, the authors examine different studies that have revealed the possible hypotheses and links in the development of neurological disorders associated with the gut microbiome.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"1 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2021-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41911683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Bahadoram, M. Mahmoudian-sani, B. Keikhaei, K. Alikhani, S. Bahadoram
{"title":"The antimigraine action of arginine-vasopressin: a theoretical basis","authors":"M. Bahadoram, M. Mahmoudian-sani, B. Keikhaei, K. Alikhani, S. Bahadoram","doi":"10.2217/fnl-2020-0017","DOIUrl":"https://doi.org/10.2217/fnl-2020-0017","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/fnl-2020-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48975470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Correll, K. Demyttenaere, A. Fagiolini, G. Hajak, S. Pallanti, G. Racagni, Swaran Singh
{"title":"Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives","authors":"C. Correll, K. Demyttenaere, A. Fagiolini, G. Hajak, S. Pallanti, G. Racagni, Swaran Singh","doi":"10.2217/fnl-2020-0012","DOIUrl":"https://doi.org/10.2217/fnl-2020-0012","url":null,"abstract":"In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"1 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44111157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}